✦ LIBER ✦

Predictors of 5-year survival and curability in small cell lung cancer

✍ Scribed by J. P. A. Crown; A. Phillippe Chahinian; I. S. Jaffrey; O. J. Glidewell; M. Kaneko; J. F. Holland

Publisher: John Wiley and Sons
Year: 1990
Tongue: English
Weight: 477 KB
Volume: 66
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19900715)66:2<382::aid-cncr2820660231>3.0.co;2-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Plasma cea levels in small cell lung can

Plasma cea levels in small cell lung cancer. Correlation with stage, distribution of metastases, and survival

✍ Jacob J. Lokich 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB 👁 2 views

Ten-year survival in lung cancer. A stud

Ten-year survival in lung cancer. A study of 56 cases

✍ William L. Watson 📂 Article 📅 1965 🏛 John Wiley and Sons 🌐 English ⚖ 243 KB 👁 1 views

5-fluorouracil, etoposide, and cisplatin

5-fluorouracil, etoposide, and cisplatin in the management of metastatic non-small cell lung cancer

✍ Lawrence Flaherty; Antoinette Wozniak; Bruce Redman; Michael Kraut; Silvana Mart 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 339 KB 👁 2 views

Etoposide in the management of non-small

Etoposide in the management of non-small cell lung cancer

✍ John C. Ruckdeschel 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 387 KB 👁 2 views

Phase II trial of edatrexate in small ce

Phase II trial of edatrexate in small cell lung cancer

✍ Martin Wiesenfeld; James R. Jett; John Q. Su; Theodore A. Braich; Carl G. Kardin 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB 👁 2 views

Survival in operable non-small-cell lung

Survival in operable non-small-cell lung cancer: Role of p53 mutations, tobacco smoking and asbestos exposure

✍ Thanos Sioris; Kirsti Husgafvel-Pursiainen; Antti Karjalainen; Sisko Anttila; An 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 68 KB 👁 2 views

Validated markers are needed to identify operable lung cancer patients with poor prognosis. About one-half of nonsmall-cell lung cancers (NSCLCs) carry a mutation in the p53 tumor-suppressor gene. We examined 101 NSCLC patients for surgical stage, completeness of resection, tobacco smoking, asbestos